Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | MAP3K12 | Q12852 | 6/20 | 0.38 |
| ▸ | SYK | P43405 | 4/20 | 0.36 |
| ▸ | KHK | P50053 | 3/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4930774 | 1.00 | CHRM4 (0.38) | CHRM4MAP3K12SYKKHKHRH4 | |
| SCHEMBL4928254 | 0.88 | SYK (0.45) | CHRM4MAP3K12SYKKHK | |
| SCHEMBL3877824 | 0.86 | MALT1 (0.41) | CHRM4MAP3K12SYKKHKPTPN11 | |
| SCHEMBL3878956 | 0.83 | MALT1 (0.38) | CHRM4MAP3K12SYKKHK | |
| SCHEMBL3878041 | 0.83 | MALT1 (0.44) | CHRM4MAP3K12 | |
| SCHEMBL4929517 | 0.83 | HRH4 (0.41) | HRH4PTPN11 | |
| SCHEMBL908061 | 0.82 | CASP1 (0.39) | MAP3K12KHKHRH4PTPN11 | |
| SCHEMBL908009 | 0.82 | MAP3K12 (0.38) | MAP3K12KHKHRH4CHRNB1CHRNB2 | |
| SCHEMBL3875754 | 0.82 | TRPV1 (0.37) | CHRM4MAP3K12KHK | |
| SCHEMBL3518558 | 0.81 | MGLL (0.39) | CHRM4MAP3K12KHKCHRNB1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-05-29 | — | — | US | disclosed |
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-05-29 | — | — | US | disclosed |
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | PIGO, GPR52, GPR88 | CHRM4 1324/4885MAP3K12 2454/4885SYK 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.